Impact of obesity on infarct size, circulating biomarkers, mitochondrial function and mortality in a Göttingen minipig myocardial infarct model
Open Access
- 27 March 2025
- journal article
- research article
- Published by Springer Nature in Lab Animal
- Vol. 54 (4) , 103-111
Abstract
Obesity is a risk factor for the development of coronary artery disease and myocardial infarction (MI). However, most large animal studies of MI are performed in lean animals. Here we assessed the impact of obesity on echocardiographic findings, infarct size, circulating biomarkers, mitochondrial respiratory capacity and mortality in a closed-chest minipig model of MI. The initial study population consisted of 20 obese (median 60.0 kg [interquartile range 55.9–64.6 kg]) and 18 lean (25.0 kg [23.4–36.5 kg]) female Göttingen minipigs. The duration of obesity induction using a western-style diet was up to approximately 6 months (156 days [24–162 days]) before the induction of MI. The induction of MI by 120-min balloon occlusion of the left anterior descending coronary artery was feasible in 17 lean and 17 obese animals. Mortality was higher in obese compared with lean animals (53% versus 12%), driven primarily by refractory ventricular fibrillation during occlusion. Electrocardiographic findings showed longer QRS and QT intervals and more extensive ST-segment elevation in obese animals compared with lean animals during occlusion. Plasma concentrations of pro-atrial natriuretic peptide, pro-C-type natriuretic peptide and cardiac troponin T were significantly lower in obese compared with lean animals. Infarct size estimated 8 weeks after MI was significantly smaller in obese (10% [9–11%]) compared with lean animals (13% [13–15%]). Finally, mitochondrial-complex-I-linked respiratory capacity was overall significantly higher in obese animals; however, no group difference was found in intrinsic mitochondrial respiratory capacity.Keywords
Funding Information
- Innovationsfonden (9066-00032B, 9066-00032B, 9066-00032B, 9066-00032B, 9066-00032B, 9066-00032B, 9066-00032B, 9066-00032B, 9066-00032B, 9066-00032B, 9066-00032B)
- Novo Nordisk A/S and the Novo Nordisk In Vivo Pharmacology LifePharm Centre at University of Copenhagen
This publication has 55 references indexed in Scilit:
- Quantifying energy expenditure in Göttingen Minipigs with the 13C-bicarbonate method under basal and drug-treated conditionsClinical Nutrition ESPEN, 2023
- Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotectionBasic Research in Cardiology, 2018
- Body mass index, abdominal fatness, and the risk of sudden cardiac death: a systematic review and dose–response meta-analysis of prospective studiesEuropean Journal of Epidemiology, 2018
- Obesity, Subclinical Myocardial Injury, and Incident Heart FailureJACC: Heart Failure, 2014
- Impact of overweight on myocardial infarct size in patients undergoing primary percutaneous coronary intervention: A magnetic resonance imaging studyAtherosclerosis, 2014
- Association between obesity and infarct size: Insight into the obesity paradoxInternational Journal of Cardiology, 2013
- Body Mass Index and Mortality in Acute Myocardial Infarction PatientsThe American Journal of Medicine, 2012
- A general introduction to the biochemistry of mitochondrial fatty acid β‐oxidationJournal of Inherited Metabolic Disease, 2010
- Patients with type 2 diabetes have normal mitochondrial function in skeletal muscleDiabetologia, 2007
- Early phase acute myocardial infarct size quantification: Validation of the triphenyl tetrazolium chloride tissue enzyme staining techniqueAmerican Heart Journal, 1981